Singapore markets close in 2 hours 57 minutes
Straits Times Index
3,347.18 +10.59 (+0.32%) Nikkei
38,945.08 +457.18 (+1.19%) Hang Seng
18,488.50 +408.89 (+2.26%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,661.98 +954.23 (+1.41%) CMC Crypto 200
1,483.79 +15.86 (+1.08%)
FULC Dec 2024 7.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 3.1100 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.1100 - 3.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
ZacksWall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
© 2024 Yahoo. All rights reserved.